Senate - 11/15/2010 Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (All Actions)
Tracker:
This bill has the status Passed House
Here are the steps for Status of Legislation:
Introduced
Array
(
[actionDate] => 2010-09-28
[displayText] => Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 111-631.
[externalActionCode] => 5000
[description] => Introduced
[chamberOfAction] => House
)
Passed House
Array
(
[actionDate] => 2010-09-30
[displayText] => Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR 9/28/2010 H7191)
[externalActionCode] => 8000
[description] => Passed House
[chamberOfAction] => House
)
PDF(PDF provides a complete and accurate display of this text.)Tip?
Shown Here: Referred in Senate (11/15/2010)
111th CONGRESS 2d Session
H. R. 2408
IN THE SENATE OF THE UNITED
STATES
November 15, 2010
Received; read twice and referred to the
Committee on Health, Education, Labor,
and Pensions
AN ACT
To expand the research and awareness
activities of the National Institute of Arthritis and Musculoskeletal and Skin
Diseases and the Centers for Disease Control and Prevention with respect to
scleroderma, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1.Short title.
This Act may be cited as the
“Scleroderma Research and Awareness Act
of 2010”.
SEC. 2. National
institute of arthritis and musculoskeletal and skin diseases; scleroderma
research expansion.
Part B of
title IV of the Public Health Service Act (42 U.S.C. 284 et seq.) is amended by
adding at the end the following:
“SEC. 409K. Scleroderma
research.
“The Director of NIH
may expand, intensify, and coordinate the activities of the National Institutes
of Health with respect to scleroderma, with particular emphasis on the
following:
“(1) Research focused
on the etiology of scleroderma and the development of new treatment options.
“(2) Clinical research
to evaluate new treatments options.
“(3) Basic research on
the relationship between scleroderma and secondary conditions such as pulmonary
hypertension, gastroparesis, Raynaud's phenomenon, Sjögren's Syndrome, and
other diseases as determined by the
Director.”.
SEC. 3. Promoting public
awareness of scleroderma.
Part
P of title III of the Public Health Service Act (42 U.S.C. 280g et seq.) is amended
by adding at the end the following:
“SEC. 399V–5. Promoting
public awareness of scleroderma.
“The Secretary may carry out an educational
campaign to increase public awareness of scleroderma. Print, video, and
Web-based materials distributed through this campaign may include—
“(1) basic information
on scleroderma and its symptoms; and
“(2) information
on—
“(A) the incidence and
prevalence of scleroderma;
“(B) diseases and
conditions affiliated with scleroderma; or
“(C) the importance of
early diagnosis and treatment of
scleroderma.”.
Passed the House of Representatives September 30
(legislative day September 29), 2010.